Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target

Paolo, A. Di; Vignini, Arianna; Alia, Sonila; Membrino, Valentina; Carpini, Giovanni Delli; Giannella, Luca; Ciavattini, Andrea

doi:10.3390/ijms232113538

Cited by 7 publications

(4 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid that originates from sphingomyelin catabolism. It plays a role in the growth of various cells, including those involved in endometriosis or adenomyosis [ 32 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review

Mitranovici,

Chiorean,

Moraru

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Endometriosis and adenomyosis behave similarly to cancer. No current treatments represent a cure, even if there are several options, including hormonal and surgical therapy. In advanced or recurrent pathologies, however, personalized treatment is necessary. We have found that due to the multiple common features, various therapeutic options have been used or studied for all three pathologies, with varying results. The objective of this review is to extract from the relevant literature the compounds that are used for endometriosis and adenomyosis characterized by malignant behavior, with some of these drugs being studied first in the treatment of endometrial cancer. Special attention is needed in the pathogenesis of these pathologies. Despite the multiple drugs that have been tested, only a few of them have been introduced into clinical practice. An unmet need is the cure of these diseases. Long-time treatment is necessary because symptoms persist, and surgery is often followed by postoperative recurrence. We emphasize the need for new, effective, long-term treatments based on pathogeny while considering their adverse effects.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Due to the heterogeneity of symptoms, there’s often a delay in diagnosis, and available therapeutic options are not curative. Currently, there’s increased emphasis on understanding the pathogenesis of these diseases [ 1 , 32 , 60 , 66 ].…”

Section: Discussionmentioning

confidence: 99%

Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review

Mitranovici,

Chiorean,

Moraru

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Since the importance of S1P in cancer varies depending on the cancer type, subtype, degree of progression, presence or absence of metastases and the organs to which it spreads, and the cancer microenvironment, clinical application of therapies targeting S1P signaling will require identifying the patient population for whom the therapy will be most effective [ 230 , 231 ]. Therefore, the development of therapies targeting S1P signaling requires the selection of target patient groups, the development of S1P signaling inhibitors, and consideration of combination therapy with anti-cancer drugs and molecular-targeted drugs.…”

Section: Targeting S1p As Therapy For Advanced Breast Cancermentioning

confidence: 99%

Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer

Nagahashi,

Miyoshi

2024

IJMS

View full text Add to dashboard Cite

In recent years, newly emerging therapies, such as immune checkpoint inhibitors and antibody-drug conjugates, have further improved outcomes for breast cancer patients. However, recurrent and metastatic breast cancer often eventually develops resistance to these drugs, and cure is still rare. As such, the development of new therapies for refractory breast cancer that differ from conventional mechanisms of action is necessary. Sphingosine-1-phosphate (S1P) is a key molecule with a variety of bioactive activities, including involvement in cancer cell proliferation, invasion, and metastasis. S1P also contributes to the formation of the cancer microenvironment by inducing surrounding vascular- and lymph-angiogenesis and regulating the immune system. In this article, we outline the basic mechanism of action of S1P, summarize previous findings on the function of S1P in cancer cells and the cancer microenvironment, and discuss the clinical significance of S1P in breast cancer and the therapeutic potential of targeting S1P signaling.

show abstract

“…S1P promotes fibrosis in cells such as macrophages, fibroblasts, and skeletal muscle precursors, mainly by binding to pro-inflammatory cytokines such as TNF-α. In turn, it stimulates the synthesis of interleukin-1β and TGF-β in cells ( 151 ). The disruption of S1P pathway is the basis of systemic chronic metabolic inflammatory diseases, including diabetes and gastrointestinal cancer, which provides sufficient evidence for using S1P pathway modulators in treating pathological inflammation ( 152 ).…”

Section: S1p Receptor Modulators In Inflammatory Diseasesmentioning

confidence: 99%

How do sphingosine-1-phosphate affect immune cells to resolve inflammation?

Sun,

Wang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Inflammation is an important immune response of the body. It is a physiological process of self-repair and defense against pathogens taken up by biological tissues when stimulated by damage factors such as trauma and infection. Inflammation is the main cause of high morbidity and mortality in most diseases and is the physiological basis of the disease. Targeted therapeutic strategies can achieve efficient toxicity clearance at the inflammatory site, reduce complications, and reduce mortality. Sphingosine-1-phosphate (S1P), a lipid signaling molecule, is involved in immune cell transport by binding to S1P receptors (S1PRs). It plays a key role in innate and adaptive immune responses and is closely related to inflammation. In homeostasis, lymphocytes follow an S1P concentration gradient from the tissues into circulation. One widely accepted mechanism is that during the inflammatory immune response, the S1P gradient is altered, and lymphocytes are blocked from entering the circulation and are, therefore, unable to reach the inflammatory site. However, the full mechanism of its involvement in inflammation is not fully understood. This review focuses on bacterial and viral infections, autoimmune diseases, and immunological aspects of the Sphks/S1P/S1PRs signaling pathway, highlighting their role in promoting intradial-adaptive immune interactions. How S1P signaling is regulated in inflammation and how S1P shapes immune responses through immune cells are explained in detail. We teased apart the immune cell composition of S1P signaling and the critical role of S1P pathway modulators in the host inflammatory immune system. By understanding the role of S1P in the pathogenesis of inflammatory diseases, we linked the genomic studies of S1P-targeted drugs in inflammatory diseases to provide a basis for targeted drug development.

show abstract

Pathogenic Role of the Sphingosine 1-Phosphate (S1P) Pathway in Common Gynecologic Disorders (GDs): A Possible Novel Therapeutic Target

Cited by 7 publications

References 84 publications

Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review

Shared Pathogenic and Therapeutic Characteristics of Endometriosis, Adenomyosis, and Endometrial Cancer: A Comprehensive Literature Review

Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer

How do sphingosine-1-phosphate affect immune cells to resolve inflammation?

Contact Info

Product

Resources

About